Finance

Lists
Why is NOV up 2.42%?
Dive Deeper
NOV:ETR
Novo Nordisk A/S
€ 34.27
+2.42%
(+0.81) 1D
10-р сарын 9, 17:35:55 (GMT+2)  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOV...
Open
€ 33.82
High
€ 34.46
Low
€ 33.76
Mkt. cap
128.45Т
Avg. vol.
181.05 мян
Volume
125.83 мян
52-wk high
€ 54.87
52-wk low
€ 30.24
No. of employees
67 мян
Open
€ 33.82
High
€ 34.46
Low
€ 33.76
Mkt. cap
128.45Т
Avg. vol.
181.05 мян
Volume
125.83 мян
52-wk high
€ 54.87
52-wk low
€ 30.24
No. of employees
67 мян
News stories
From web sources and news partners
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7 мян
Founded1923 оны 12-р сарын 21
HeadquartersBagsværd, Capital Region of Denmark, Дани
SectorPharmaceutical industry
Last report
2026 оны 8-р сарын 5
Fiscal period
Q2 2026
DKK 6.18 / DKK 5.03
+22.87%beat
Revenue / Est. (DKK)
78.49 тэрбум / 71.45 тэрбум
+9.86%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
74.98 тэрбум
79.14 тэрбум
96.82 тэрбум
78.49 тэрбум
Cost of goods sold
14.47 тэрбум
14.17 тэрбум
13.60 тэрбум
17.10 тэрбум
Cost of revenue
14.47 тэрбум
14.17 тэрбум
13.60 тэрбум
17.10 тэрбум
Research and development expenses
11.49 тэрбум
12.67 тэрбум
10.28 тэрбум
11.46 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.76 тэрбум
17.14 тэрбум
13.22 тэрбум
16.31 тэрбум
Operating expense
27.25 тэрбум
29.73 тэрбум
23.61 тэрбум
28.00 тэрбум
Total operating expenses
41.72 тэрбум
43.90 тэрбум
37.20 тэрбум
45.10 тэрбум
Operating income
33.25 тэрбум
35.24 тэрбум
59.62 тэрбум
33.39 тэрбум
Other non operating income
1.53 тэрбум
-241.00 сая
-
-
EBT including unusual items
25.52 тэрбум
34.18 тэрбум
62.17 тэрбум
26.88 тэрбум
EBT excluding unusual items
35.09 тэрбум
37.62 тэрбум
62.17 тэрбум
33.20 тэрбум
Income tax expense
5.51 тэрбум
7.29 тэрбум
13.62 тэрбум
5.89 тэрбум
Effective tax rate
21.60%
21.34%
21.90%
21.90%
Other operating expenses
-
-81.00 сая
106.00 сая
234.00 сая
Net income
20.01 тэрбум
26.89 тэрбум
48.56 тэрбум
20.99 тэрбум
Net profit margin
26.68%
33.98%
50.15%
26.74%
Earnings per share
4.50
6.04
6.63
6.18
Interest and investment income
307.00 сая
4.41 тэрбум
-
1.31 тэрбум
Interest expense
-
-4.97 тэрбум
-
-1.50 тэрбум
Net interest expenses
307.00 сая
-560.00 сая
-
-186.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
36.49 тэрбум
36.66 тэрбум
63.13 тэрбум
36.99 тэрбум
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс